Skip to main content
Dryad

Data from: uPAR as a novel immunotherapeutic target in recurrent glioblastoma

Data files

May 04, 2026 version files 8.06 GB

Click names to download individual files

Abstract

Glioblastoma (GBM) comprises nearly 15% of primary CNS tumors, and 50% of malignant primary CNS tumors worldwide. Considerable tumoral heterogeneity exists within GBM, leading to inefficacy of current treatments, and the absence of meaningful improvements in frontline therapies in the last 20 years. Through multi-omic analysis of patient-derived primary and recurrent GBM cell lines we identify the urokinase plasminogen activator receptor (uPAR) as a pro-tumorigenic marker of putative brain tumor initiating cells and potential therapeutic target. We find that genetic disruption of uPAR expression impairs pro-tumorigenic characteristics in vitro and in vivo, and uPAR Chimeric Antigen Receptor (CAR) T cells demonstrate potent activity against recurrent GBM patient-derived xenograft models, significantly increasing survival. Notably, uPAR is expressed on GBM-associated macrophages, extending the potential of uPAR CAR Ts to target both GBM and its cognate tumor microenvironment (TME). Together, these data illustrate the potency and therapeutic potential of targeting uPAR in GBM.